ClinicalTrials.gg
RecruitingNCT03601286Updated Oct 12, 2023

Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency

A Phase 1 interventional study of Lentiviral vector transduced CD34+ cells in Severe Combined Immunodeficiency, X-Linked, sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to male participants aged 8 Weeks to 5 Years. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Dec 2018; still recruiting 7 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
8 Weeks to 5 Years
Sex
Male
01

Study summary

Severe combined immunodeficiency disorder (SCID) is a heterogeneous group of inherited disorders characterized by a profound reduction or absence of T lymphocyte function, resulting in lack of both cellular and humoral immunity. SCID arises from a variety of molecular defects which affect lymphocyte development and function. The most common form of SCID is an X-linked form (SCID-X1), which accounts for 30-50% of all cases. SCID-X1 is caused by defects in the common cytokine receptor gamma chain, which was originally identified as a component of the high affinity interleukin-2 receptor (IL2RG).

Allogeneic haematopoietic stem cell transplantation (HSCT), which replaces the patient's bone marrow with that of a healthy donor, is the only treatment that definitively restores the normal function of the bone marrow. HSCT is the first choice of treatment for patients with signs of bone marrow failure and a fully-matched related donor. However, patients without a fully-matched related donor have much worse overall outcomes from HSCT.

This study will investigate whether patients with SCID-X1 without a fully matched related donor may benefit from gene therapy. To do this the investigators propose to perform a phase I/II clinical trial to evaluate the safety and efficacy (effect) of gene therapy for SCID-X1 patients using a lentivirus delivery system containing the IL2RG gene. Up to 5 eligible SCID-X1 patients will undergo mobilisation and harvest of their haematopoietic stem precursor cells (HPSCs). In the laboratory the disabled lentivirus will be used to insert a normal human IL2RG gene into the patient's harvested HPSCs. Patients will receive chemotherapy conditioning prior to cell infusion, in order to enhance grafting. The genetically corrected stem cells will then be re-infused into the patient. Patients will be followed up for 2 years. This trial will determine whether gene therapy for SCID-X1 using a lentiviral vector is safe, feasible and effective

02

Conditions studied

  • Severe Combined Immunodeficiency, X-Linked
03

In context

X-Linked Combined Immunodeficiency Diseases

28 studies on the registry are indexed under X-Linked Combined Immunodeficiency Diseases; 9 are open to participants now.

This study's planned enrollment of 5 is below the median of 9 across 16 interventional studies indexed under X-Linked Combined Immunodeficiency Diseases.

Browse X-Linked Combined Immunodeficiency Diseases studies →

Lead sponsor

Great Ormond Street Hospital for Children NHS Foundation Trust is the lead sponsor of 82 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Weeks to 5 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of SCID-X1 based on immunophenotype and lack of T cell function (proliferation to PHA \<10% of the lower limit of normal for the laboratory) AND confirmed by a mutation in IL2RG
  2. Lack of an HLA identical (A, B, C, DR, DQ) related donor
  3. Age \<5 years
  4. Signed
  5. Documentation of willingness to follow up for 15 years post-infusion
  6. If the patient has previously undergone transplant or gene therapy, insufficiency of graft-derived T cell engraftment must be documented.
  7. Age at least 8 weeks of age by the time of busulfan administration

Exclusion criteria

Exclusion Criteria:

  1. Patients with an active, therapy-resistant infection. Infections that are known to be highly morbid in SCID patients will be considered active and therapy-resistant if the infectious agent is repeatedly isolated despite a minimum of 2 weeks of appropriate therapy and is associated with significant organ dysfunction (including but not limited to abnormalities listed below).

    1. Mechanical ventilation including continuous positive airway pressure
    2. Abnormal liver function defined by and ALT >10 times the upper range of normal OR >2 mg/dL
    3. Shortening fraction on echocardiogram \<25% or \<50%
    4. Renal failure defined as \<30 ml/min/1.73 m2 or dialysis dependence
  2. Uncontrolled seizure disorder
  3. Encephalopathy
  4. Documented coexistence of any disorder known to affect DNA repair
  5. Diagnosis of active malignant disease other than EBV-associated lymphoproliferative disease
  6. Patients with evidence of infection with -1
  7. Previous transplant with cytoreductive chemotherapy
  8. Major (life-threatening) congenital anomalies. Examples of "major (life-threatening) congenital anomalies" include, but are not limited to: unrepaired cyanotic heart disease, hypoplastic lungs, anencephaly or other major central nervous system malformations, other severe non-repairable malformations of the gastrointestinal or genitourinary tracts that significantly impair organ function.
  9. Other conditions which in the opinion of the P.I. or Co-investigators, contra-indicate collection and/or infusion of transduced cells or indicate patient's inability to follow the protocol. These may include for example clinical ineligibility to receive anaesthesia, severe deterioration of clinical condition of the patient after collection of bone marrow but before infusion of transduced cells, or documented refusal or inability of the family to return for scheduled visits. There may be other unforeseen rare circumstances that would result in exclusion of the patient, such as sudden loss of legal guardianship.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Lentiviral vector transduced CD34+ cells

    Single arm, non-randomised cohort of up to 5 patients with X-linked Severe Combined Immunodeficiency. CD34+ cells will be collected via bone marrow harvest or leukapheresis. The collected cells will then be purified, cultured and transduced with the G2SCID lentiviral vector. Transduced cells will be frozen. A minimum of 2.5 x 106/kg CD34+ cells after transduction with a minimum transduction efficiency of 0.7 copies/cell is required for infusion into the patient. The patient will receive non-myeloablative conditioning with intravenous busulfan the two or three days prior to cell infusion. The frozen cells will be thawed on the day of infusion and the cells administered according to hospital procedures. The patient will remain in hospital until sufficient cover of the patient's immune system

    Drug: Lentiviral vector transduced CD34+ cells

Interventions

  • DrugLentiviral vector transduced CD34+ cells

    Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.

    Also known as: G2SCID lentiviral vector transduced CD34+ cells

06

What researchers measure

Primary outcomes

  1. Measure event-free survival after 1 year after gene transfer

    Event-free survival at 1 year post-infusion. Events will include death, infusion of unmanipulated back-up product for failure of haematopoietic recovery, and allogeneic transplant performed for poor immune reconstitution

    Time frame: 1 year

  2. Measure T cell immune reconstitution: CD3+ T cell count

    T cell reconstitution at 1 year post-infusion: CD3+ T cell count ≥300 cells/microliter in peripheral blood

    Time frame: 1 year

  3. Measure T cell immune reconstitution; gene marking

    T cell reconstitution at 1 year post-infusion: Gene marking ≥0.1 copies/cell in sorted CD3+ T cells

    Time frame: 1 year

Secondary outcomes

  1. Measure overall survival

    Measure overall survival at 2 years post-infusion

    Time frame: 2 years

  2. Measure event-free survival

    Measure event-free survival at 2 years post-infusion

    Time frame: 2 years

  3. Incidence of adverse events related to gene therapy

    Incidence of adverse events related to gene therapy

    Time frame: up to 2 years post-infusion of gene therapy

  4. Enumeration of absolute lymphocyte count determined by routine complete reconstitution

    Enumeration of absolute lymphocyte count determined by routine complete blood counts (CBC)

    Time frame: up to 2 years post-infusion of gene therapy

  5. Haematopoietic recovery after receipt of busulfan

    Haematopoietic recovery is defined as absolute neutrophil count above 0.5 x10\^9 /l for three consecutive days, achieved within 6 weeks following infusion.

    Time frame: up to 6 weeks post-infusion of gene therapy

  6. Measure absolute numbers of T, B and NK lymphocytes

    Absolute numbers of T, B and NK lymphocytes

    Time frame: up to 2 years post-infusion of gene therapy

  7. Calculate percentage of naïve and memory T cell subsets

    Percentage of naïve and memory T cell subsets

    Time frame: up to 2 years post-infusion of gene therapy

  8. Measure laboratory results which correlates with efficacious immune reconstitution

    Percentage of naïve and memory B cell subsets

    Time frame: up to 2 years post-infusion of gene therapy

  9. Determine Freedom from immunoglobulin substitution for at least 9 months

    Freedom from immunoglobulin substitution for at least 9 months

    Time frame: 2 years post-infusion of gene therapy

  10. Measure serum immunoglobulin levels reconstitution

    Serum immunoglobulin levels

    Time frame: up to 2 years post-infusion of gene therapy

  11. Measure proliferation of lymphocytes to phytohaemagglutinin determined by titrated thymidine incorporation reconstitution

    Proliferation of lymphocytes to phytohaemagglutinin determined by titrated thymidine incorporation

    Time frame: up to 2 years post-infusion of gene therapy

  12. Measure antigen specific antibody titres to tetanus toxoid reconstitution

    Measure antigen specific antibody titres to tetanus toxoid

    Time frame: up to 2 years post-infusion of gene therapy

  13. Measure T cell receptor excision circles (TREC)

    Measure T cell receptor excision circles (TREC)

    Time frame: up to 2 years post-infusion of gene therapy

  14. Measure T cell receptor Vb family usage

    Measure T cell receptor Vb family usage

    Time frame: up to 2 years post-infusion of gene therapy

  15. To assess the efficacy of stem cell transduction/engraftment by measuring the frequency of gene marking in peripheral blood cells

    Gene marking in specific lineages of peripheral blood cells. Genomic DNA isolated from each population will be assayed for VCN by quantitative PCR (qPCR). The results will be aggregated to determine the effectiveness of gene marking in the peripheral blood cells.

    Time frame: up to 2 years post-infusion of gene therapy

  16. Measure clonal diversity of vector integrants

    Clonal diversity will be quantitated and used to estimate the number of transduced haematopoietic stem cells that have engrafted in the subjects. Number of sequence reads and unique integration sites will be assessed to quantify population clone diversity, distribution of integration sites and relative abundance.

    Time frame: up to 2 years post-infusion of gene therapy

Other outcomes

  1. Correlation of potential biomarkers of humoral immune reconstitution with freedom from intravenous immunoglobulin substitution and antibody response to tetanus at 2 years post infusion including: Gene marking in B cells and B cell phenotype.

    Correlation of potential biomarkers of humoral immune reconstitution at 6 months, 1 year, 2 years post infusion with freedom from intravenous immunoglobulin substitution and antibody response to tetanus at 2 years post infusion including: Gene marking in B cells and B cell phenotype.

    Time frame: at 6 month, 12 month and 2 years post-infusion of gene therapy

  2. Correlation of busulfan area-under-the-curve measurements prior to infusion with freedom from intravenous immunoglobulin substitution and antibody response to tetanus at 2 years post-infusion and other markers of humoral immune reconstitution

    Correlation of busulfan area-under-the-curve measurements prior to infusion with freedom from intravenous immunoglobulin substitution and antibody response to tetanus at 2 years post-infusion and other markers of humoral immune reconstitution

    Time frame: 2 years post-infusion of gene therapy

  3. Evidence of insertion site sharing between 2 or more lineages at 1 year and 2 years post infusion

    Evidence of insertion site sharing between 2 or more lineages at 1 year and 2 years post infusion

    Time frame: 1 year and 2 years post infusion of gene therapy

  4. Correlation of gene marking and insertion site sharing in expanded peripheral blood CD34+ cells with peripheral blood mature cell samples at 1 year and 2 years post infusion

    Correlation of gene marking and insertion site sharing in expanded peripheral blood CD34+ cells with peripheral blood mature cell samples at 1 year and 2 years post infusion

    Time frame: 1 year and 2 years post infusion of gene therapy

  5. Description of T cell receptor and B cell receptor repertoire before and after infusion

    Description of T cell receptor and B cell receptor repertoire before and after infusion

    Time frame: Pre-harvest, 3 month, 6 month, 12 month and 2 years post infusion of gene therapy

  6. Description of NK cell function and phenotype before and after infusion

    Description of NK cell function and phenotype before and after infusion

    Time frame: Pre-harvest, 3 month, 6 month, 12 month and 2 years post infusion of gene therapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2018 (actual). Primary completion is estimated for Aug 2026, 92 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2018
First posted
Jul 26, 2018
StartActual
Dec 21, 2018
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Oct 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03601286
Lead sponsor
Great Ormond Street Hospital for Children NHS Foundation Trust
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Dec 21, 2018
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Oct 12, 2023

Study contacts

Claire Booth, Dr
Contact
c.booth@ucl.ac.uk
0207 905 2198
Karen Oprych, Dr
Contact
k.gladwin@ucl.ac.uk
Claire Booth, Dr
principal investigator · UCL Great Ormond Street Institute of Child Health
Adrian Thrasher, Prof
principal investigator · UCL Great Ormond Street Institute of Child Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion